Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 2
2000 1
2001 3
2002 4
2003 3
2004 3
2005 8
2006 9
2007 4
2008 8
2009 12
2010 13
2011 16
2012 15
2013 19
2014 16
2015 18
2016 19
2017 13
2018 16
2019 16
2020 11
2021 12
2022 8
2023 10
2024 7
2025 10
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Aflibercept--a decoy VEGF receptor.
Ciombor KK, Berlin J. Ciombor KK, et al. Curr Oncol Rep. 2014 Feb;16(2):368. doi: 10.1007/s11912-013-0368-7. Curr Oncol Rep. 2014. PMID: 24445500 Free PMC article. Review.
Aflibercept (known as ziv-aflibercept in the USA and sold under the trade name Zaltrap) is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factors A and B and …
Aflibercept (known as ziv-aflibercept in the USA and sold under the trade name Zaltrap) is a human recombinant fusion protein with antiangio …
A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy.
Guo XF, Zhang YY, Kang J, Dou QH, Zhu XF. Guo XF, et al. J Drug Target. 2022 Mar;30(3):302-312. doi: 10.1080/1061186X.2021.1961791. Epub 2021 Aug 9. J Drug Target. 2022. PMID: 34319822
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) represent two clinically validated targets for a variety of human cancers, and dual inhibition of EGFR and VEGF(R) has de …
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor …
VEGFR1 signaling in retinal angiogenesis and microinflammation.
Uemura A, Fruttiger M, D'Amore PA, De Falco S, Joussen AM, Sennlaub F, Brunck LR, Johnson KT, Lambrou GN, Rittenhouse KD, Langmann T. Uemura A, et al. Prog Retin Eye Res. 2021 Sep;84:100954. doi: 10.1016/j.preteyeres.2021.100954. Epub 2021 Feb 25. Prog Retin Eye Res. 2021. PMID: 33640465 Free PMC article. Review.
Five vascular endothelial growth factor receptor (VEGFR) ligands (VEGF-A, -B, -C, -D, and placental growth factor [PlGF]) constitute the VEGF family. VEGF-A binds VEGF receptors 1 and 2 (VEGFR1/2) …
Five vascular endothelial growth factor receptor (VEGFR) ligands (VEGF-A, -B, -C, -D, and placenta …
The VEGF decoy receptor soluble Fms-like tyrosine kinase 1 binds to macrophages.
van Aanhold CCL, Yong Q, Landman L, Sardana S, Bouwmeester AB, Dijkstra KL, Wolterbeek R, Mei H, Tjokrodirijo RTN, de Ru AH, van Veelen PA, Bruijn JA, van Kooten C, Baelde HJ. van Aanhold CCL, et al. Angiogenesis. 2025 May 2;28(3):28. doi: 10.1007/s10456-025-09980-w. Angiogenesis. 2025. PMID: 40314836 Free PMC article.
BACKGROUND: Soluble Fms-like Tyrosine kinase-1 (sFLT1) is a native inhibitor of VEGF, best known for its antiangiogenic effects in preeclampsia. sFLT1 also reduces chronic inflammation and promotes tissue repair. ...Alternative activation of macrophages by IL-4 strongly in …
BACKGROUND: Soluble Fms-like Tyrosine kinase-1 (sFLT1) is a native inhibitor of VEGF, best known for its antiangiogenic effects in pr …
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.
Estrada CC, Maldonado A, Mallipattu SK. Estrada CC, et al. J Am Soc Nephrol. 2019 Feb;30(2):187-200. doi: 10.1681/ASN.2018080853. Epub 2019 Jan 14. J Am Soc Nephrol. 2019. PMID: 30642877 Free PMC article. Review.
Inhibition of vascular endothelial growth factor A (VEGFA)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling is a common therapeutic strategy in oncology, with new drugs continuously in development. ... …
Inhibition of vascular endothelial growth factor A (VEGFA)/vascular endothelial growth f …
Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span.
Grunewald M, Kumar S, Sharife H, Volinsky E, Gileles-Hillel A, Licht T, Permyakova A, Hinden L, Azar S, Friedmann Y, Kupetz P, Tzuberi R, Anisimov A, Alitalo K, Horwitz M, Leebhoff S, Khoma OZ, Hlushchuk R, Djonov V, Abramovitch R, Tam J, Keshet E. Grunewald M, et al. Science. 2021 Jul 30;373(6554):eabc8479. doi: 10.1126/science.abc8479. Science. 2021. PMID: 34326210
Aging is an established risk factor for vascular diseases, but vascular aging itself may contribute to the progressive deterioration of organ function. Here, we show in aged mice that vascular endothelial growth factor (VEGF …
Aging is an established risk factor for vascular diseases, but vascular aging itself may contribute to the progressive …
Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH, Lee MY, Seo Y, Hong HJ, An HJ, Kang JS, Kim HM. Lee DH, et al. Biomaterials. 2018 Jul;171:34-45. doi: 10.1016/j.biomaterials.2018.04.029. Epub 2018 Apr 16. Biomaterials. 2018. PMID: 29679794
Limitation of current anti-Vascular Endothelial Growth Factor (VEGF) cancer therapy is transitory responses, inevitable relapses and its insufficient tumor-targeting. ...Here, we developed a novel multi-paratopic VEGF decoy rece …
Limitation of current anti-Vascular Endothelial Growth Factor (VEGF) cancer therapy is transitory respons …
Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity.
Konner J, Dupont J. Konner J, et al. Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5. doi: 10.3816/ccc.2004.s.013. Clin Colorectal Cancer. 2004. PMID: 15479484 Review.
Angiogenesis is regulated by a number of soluble factors, the relative proportions of which can exacerbate or inhibit the process. Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, produced by the majority of huma …
Angiogenesis is regulated by a number of soluble factors, the relative proportions of which can exacerbate or inhibit the process. Vascul …
Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.
Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Jena MK, et al. Biomolecules. 2020 Jun 24;10(6):953. doi: 10.3390/biom10060953. Biomolecules. 2020. PMID: 32599856 Free PMC article. Review.
Abnormal spiral artery remodeling, placental ischemia and a resulting increase in the circulating levels of vascular endothelial growth factor receptor-1 (VEGFR-1), also called soluble fms-like tyrosine kinase-1 (sFlt-1), are believed to be amon …
Abnormal spiral artery remodeling, placental ischemia and a resulting increase in the circulating levels of vascular endothelial …
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Papadopoulos N, et al. Angiogenesis. 2012 Jun;15(2):171-85. doi: 10.1007/s10456-011-9249-6. Angiogenesis. 2012. PMID: 22302382 Free PMC article.
Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis and vascular leak associated with cancers and various eye diseases. However, little information is currently available on the binding kinetics and relative biological activity …
Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis and vascular leak associated with c …
250 results